Companies /Healthcare

Abivax

NASDAQ: ABVX Biotechnology
$88.15
▼ $0.90 (−1.01%) today
Markets closed · 11:40pm ET

ABVX at a Glance

Valuation
Market cap
$7.8B
Profitability
Revenue (TTM)
$4.7M
EPS (TTM)
$-6.08
Price
52-week range
$70 – $149
Street target
$164.00

Headquartered in 7-11 Boulevard Haussmann, Paris Fiscal year ends December NASDAQ: ABVX abivax.com

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis (UC) and in Phase 2b trials for Crohn's disease (CD). Abivax is listed on both Euronext Paris and Nasdaq. The company is currently pre-revenue, investing heavily in late-stage clinical development and pre-commercial infrastructure as it prepares for a planned NDA submission for obefazimod in UC by end of 2026. Abivax operates across France and the United States and maintains a debt-free balance sheet following the completion of its royalty certificate buy-back program. Updated

Latest Activity

ABVXABIVAX Société Anonyme
Reports Mon Sep 21After close4:05 PM ETConfirmed

A $9.2 billion market cap resting almost entirely on one ulcerative colitis asset gets its update after the close at 4:05 PM ET. Cash runway and any regulatory milestone commentary are what move this one beyond the quarterly numbers.

    Read more
    Earnings on deck — Sep 21–25
    24 companies14 before open10 after close

    Tuesday and Wednesday carry the week: AutoZone, KB Home, General Mills, Paychex and Cintas all report inside 48 hours, covering car repair budgets, new home demand, grocery pricing and small business payrolls in one stretch. Of the 24 companies on deck, 14 report before the open.

    • ABVXABIVAX Société AnonymeMon Sep 21After close
    • THOTHOR Industries, Inc.Tue Sep 22Before open
    • AZOAutoZone, Inc.Tue Sep 22Before open
    • MLKNMillerKnoll, Inc. Tue Sep 22Before open
    • HEREHere Group LimitedTue Sep 22Before open
    • KBHKB HomeTue Sep 22After close
    • WORWorthington Enterprises, Inc.Tue Sep 22After close
    • AYTUAytu BioPharma, Inc.Tue Sep 22After close
    • CBRLCracker Barrel Old Country Store, Inc.Wed Sep 23Before open
    • GISGeneral Mills, Inc.Wed Sep 23Before open
    • PAYXPaychex, Inc.Wed Sep 23Before open
    • CTASCintas CorporationWed Sep 23Before open
    • MANUManchester UnitedWed Sep 23Before open
    • FULH.B. Fuller CompanyWed Sep 23After close
    • SFIXStitch Fix, Inc.Wed Sep 23After close
    Read more

    ABVX Coverage

    Frequently Asked Questions

    What does Abivax do?

    Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

    What is the ABVX stock price target?

    The Wall Street consensus 12-month price target for ABVX is $164.00.